The novel coronavirus of 2019 (SARS-CoV-2) has resulted in an increased incidence of patients admitted to intensive care units (ICUs). On average 5 percent (ranges of 3-80% have been reported) of patients with COVID-19 require ICU admission. Unfortunately, a vast majority of these ICU patients contribute to the mortality seen with this disease. The chief reason for ICU admission in COVID-19 is due to hypoxia. Infection with SARS-CoV-2 results in inflammation and damage to the lung parenchyma via the receptor angiotensin-converting enzyme 2 (ACE2) on type II pneumocytes. The resulting lung damage presents as a clinical syndrome: Acute Respiratory Distress Syndrome (ARDS). Thus, the management of COVID-19–associated ARDS has been adopted from prior studies that have assessed interventions in ARDS. Treatment of ARDS remains complex with very few studies demonstrating mortality benefits. In addition to hypoxia associated with COVID-19, the presentation will address 2 additional features of COVID-19: cytokine storm and immunothrombosis or hypercoagulability associated with COVID-19. The cytokine storm, or hyperinflammatory syndrome, associated with COVID-19 has been attributed to the exaggerated immune response to the virus that results in multiorgan dysfunction. Treatment of this hyperinflammatory syndrome has been extrapolated from cytokine release syndrome (CRS) seen in other diseases. The increased incidence of venous thromboembolism (VTE) and additional clotting seen with COVID-19 has resulted in aggressive anti-coagulation strategies in treatment of this disease. We are continuing to obtain new data on COVID-19, and the management decisions can be very institution- or provider- dependent. The goal of this presentation is to review the current data and outline some of the salient features in treatment of critically ill patients with COVID-19.